Clinical Trial Update: Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating imatinib mesylate as adjuvant therapy after complete surgical resection of gastrointestinal stromal tumor; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: COMPLETED